patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug · oligonucleotide
eplontersen sodium
Marketedupdated 2mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Approvedcommunity read0 votes
Oligonucleotide drug with a maximum clinical stage of Approval (across all indications), with an approval for familial amyloid neuropathy and polyneuropathy and 1 investigational indication.
targets
Transthyretin mRNA
all catalysts(5)
approval · 5
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that